Ratio Therapeutics
Boston
About Ratio Therapeutics
Ratio Therapeutics develops radiotherapeutics for the treatment of cancers. They engaged in research and development platforms, trillium and macropa, enable the imaging, discovery, and advancement of radiopharmaceuticals. It enables doctors to detect a wide range of epithelial-derived cancers, such as breast, pancreatic, lung, colon cancers, and more.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $90.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2024)
- Website: ratiotx.com
Industries & Categories
Biopharma, Biotechnology, Life Science, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/ratio-therapeutics-2883 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.